Recent Updates
Recently added Catalysts

Paradym CRT + Physiological Diagnosis

Phase 2

Congestive Heart Failure | Unknown | Cardiovascular |LivaNova PLC|Last Updated: May 15, 2014

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
Double-BlindUNCONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment520
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00957541Evaluation of a Diagnostic Feature in a Cardiac Resynchronization Therapy (CRT) DevicePHASE2 COMPLETED 520Sep 1, 2009Apr 1, 2013May 15, 20141 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Sensitivity of diagnostic feature in detecting heart failure events (using the device) in comparison to clinical heart failure events experienced by the patient (as classified by an independent committee).
Thirteen months
Mean number of false positives per patient per year.
Thirteen Months
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingTRIPLE
ModelSINGLE_GROUP
PurposeDIAGNOSTIC
Treatment Arms
ArmTypeDescription
CRT TherapyEXPERIMENTALAll patients will receive CRT therapy with the Physiological Diagnosis (PhD) feature enabled.
Interventions
NameTypeDescription
Paradym CRT + Physiological Diagnosis (PhD)DEVICEAll subjects will undergo CRT therapy with the Physiological Diagnosis (PhD) feature enabled.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Subject eligible for implantation of a CRT-D device according to current available guidelines for cardiac resynchronization therapy * Subject has severe heart failure (NYHA Class III or IV) * Subject has experienced at least one heart failure event within six months prior to e...

Countries:United States
Unlock Eligibility Criteria